Direct Coombs Test

Function and Overview

The Direct Coombs Test, also known as the Direct Antiglobulin Test (DAT), is used to determine whether antibodies (IgG) or complement proteins have attached to the surface of red blood cells (RBCs). Normally, antibodies should circulate in the plasma; when they bind directly to RBCs, it signals the immune system to destroy those cells, leading to hemolysis (the premature breakdown of blood cells).

Why It Is Ordered

This test is a critical tool in several specific clinical scenarios:

• Autoimmune Hemolytic Anemia (AIHA): When the body produces antibodies against its own RBCs.
• Hemolytic Disease of the Newborn (HDN): To check if a mother's antibodies have crossed the placenta and are attacking the baby's RBCs.
• Transfusion Reactions: If a patient develops a fever or dark urine after a blood transfusion, the DAT determines if the donor blood is being rejected.
• Drug-Induced Hemolysis: Certain drugs (like penicillin or methyldopa) can cause antibodies to bind to RBCs.

Associated Conditions

A positive Direct Coombs test is associated with Systemic Lupus Erythematosus (SLE), Chronic Lymphocytic Leukemia (CLL), and various lymphomas. It is also the definitive test for diagnosing Rh incompatibility in neonates. In the context of drug reactions, it may explain sudden-onset anemia in patients taking high-dose antibiotics or certain hypertension medications.